EoCene Ltd.
EOCN · XNASCIK 1595353fmd_1FWPMF19YBG2M3J3HBHTAZ3C44Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Jun 30, 2026, 37 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 1 | 2 | 0 | 0 | – | – | – | – | – |
| Research and development | 14 | 10 | 8 | 18 | 26 | 27 | 13 | 4 | 3 | 5 |
| Total operating expenses | 17 | 12 | 11 | 22 | 30 | 33 | 18 | 7 | 6 | 9 |
| Operating income | – | (12) | (11) | (22) | (30) | – | – | – | – | – |
| Other non-operating income (expense) | 0 | 0 | 1 | (2) | 1 | 0 | (0) | (1) | (1) | (1) |
| Income before taxes | (17) | (12) | (10) | (20) | (29) | (32) | 18 | 7 | 8 | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | – | – | – | – | 0 |
| Net income from continuing operations | (17) | (12) | (10) | (20) | (29) | – | – | – | – | – |
| Net income | (17) | (12) | (10) | (20) | (29) | (32) | (18) | (7) | (8) | (10) |